AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.
Funding Rounds (3) - $9.81MUpdate
|Aug 28, 2010||angiochem.com - AngioChem raises 6000000 in unknown round|
|Dec 20, 2007||mmvf.com - AngioChem Secures US $3 Million in Financing from MMV Financial, Inc.|
|Dec 12, 2005||Business Wire - AngioChem Completes a $6 Million Financing to Advance CNS Drug Development|
201 President-Kennedy Ave
Suite PK-R220, Quebec,
Montréal, QC H2X 3Y7